{"product_id":"human-astrocytes-ipsc-derived-parkinson-s-disease-patient-sporadic-bhc18500316","title":"Human Astrocytes (iPSC-derived, Parkinson's Disease Patient, Sporadic)","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eHuman Astrocytes (iPSC-derived, Parkinson's Disease Patient, Sporadic)\u003c\/strong\u003e is a cell model used for research applications where physiologically relevant identity and donor background support interpretation of experimental readouts. Human Glial associated with Parkinson's Disease Patient, Sporadic within the Nervous system.\u003c\/p\u003e\n\u003cp\u003eAstrocytes are a crucial component of the human central nervous system. Astrocytes’ diverse and heterogeneous character allows them to serve a variety of important activities during brain formation as well as afterwards in neuronal homeostasis and synaptic transmission [1] . Since they engage in the development of synapses, and neurotransmitter recycling, astrocytes are crucial for the construction and plasticity of brain circuits [2] . In addition, astrocytes are immunocompetent cells that participate in neuroinflammation by secreting cytokines and chemokines, which may have protective or detrimental consequences for neuronal survival [3] . iXCells Biotechnologies is proud to provide fully differentiated and functional human iPSC-derived human astrocytes that display typical astrocytic morphology and express key markers of e.g., GFAP, ALDH1L1 (Figure 1A,B) when cultured in the Human Astrocyte Maintenance Medium (Cat# MD-0109-100ML) . In addition, our iPSC-derived Astrocytes can also be co-cultured with cortical neurons or other cell types for drug screening platforms (Figure 1C-E) and can respond to inflammatory stimuli (Figure 2) and moreover affect neurite length of neurons when previously stimulated collected conditioned media is applied (Figure 3). Figure 1. Human iPSCs derived astrocytes show expression of characteristic biological markers. (A) Immunostaining of iPSC-derived astrocytes expressing ALDH1L1 (green), CD44 (red), S100b (red), or GFAP (green) at day 28. All cells were counterstained for DAPI (blue). Scale bars, 200 µm. (B) Quantifications for percentage of astrocytes, positive for the listed markers over DAPI. Results are expressed as means ± SEM. (C) Cortical neurons were differentiated as a monolayer on a MEA plate and co_x0002_cultured with different types of astrocytes, and subsequently neuronal activity was measured. (D) Example raster plot showing spikes (black lines) and network bursts (pink lines) in the MEA for neurons cultured with or without astrocytes. (E) At 5 days of neural differentiation, electrical parameters were measured in the MEA and the results are graphed as mean ± SEM for mean firing rate and number of spikes.\u003c\/p\u003e\n\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell identity:\u003c\/strong\u003e Glial (iPSC-Derived Cells)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSource context:\u003c\/strong\u003e Astrocytes; Nervous\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDonor background:\u003c\/strong\u003e Disease\/condition: Parkinson's Disease Patient, Sporadic\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBiosafety level:\u003c\/strong\u003e BSL-2 (follow your institution’s biosafety program and local regulations)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGrowth properties:\u003c\/strong\u003e Adherent\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eProduct-specific elements (such as tissue source, donor background, and cell classification) help frame how results should be interpreted across assays and experimental conditions.\u003c\/p\u003e\n\u003ch2\u003eBiological background\u003c\/h2\u003e\n\u003cp\u003eCells originating from the Nervous system are commonly studied to understand tissue-specific physiology, signaling, and responses to perturbations in controlled in vitro settings.\u003c\/p\u003e\u003cp\u003eAcross primary and specialty cell models, experimental outcomes can be influenced by donor heterogeneity, passage history, confluence, and media composition. For interpretation, it is common to validate key markers or functional phenotypes in the user’s assay context and to document culture variables consistently.\u003c\/p\u003e\n\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eIncreasing use of primary and specialty cells to improve translational relevance for target biology and phenotypic screening.\u003c\/li\u003e\n  \u003cli\u003eAdoption of 3D culture formats and co-culture systems to better capture tissue microenvironments and cell–cell interactions.\u003c\/li\u003e\n  \u003cli\u003eIntegration of functional readouts with single-cell and multi-omics profiling to connect phenotype with molecular state.\u003c\/li\u003e\n  \u003cli\u003eGrowth of human-relevant neural models (including glial components) to study circuit- and inflammation-linked phenotypes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon research applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eProfile identity markers by flow cytometry or immunostaining in cultured cells\u003c\/li\u003e\n  \u003cli\u003eQuantify neurite outgrowth and synaptic marker profiles in neural cultures\u003c\/li\u003e\n  \u003cli\u003eQuantify functional responses to defined stimuli relevant to the model system\u003c\/li\u003e\n  \u003cli\u003eCompare baseline phenotype across donors\/conditions using gene expression profiling\u003c\/li\u003e\n  \u003cli\u003eMeasure neuroinflammatory signaling in neuron–glia or microglia-enriched models\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eInterpretation typically focuses on how a perturbation (e.g., cytokine exposure, metabolic stress, genetic manipulation, or compound treatment) shifts marker profiles or functional readouts relative to an appropriate control matched for donor and culture variables.\u003c\/p\u003e\n\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eDonor-to-donor heterogeneity can influence baseline phenotype and treatment response; include biological replicates when feasible.\u003c\/li\u003e\n  \u003cli\u003ePassage number, confluence, and media composition can shift gene expression and functional readouts; track and report these variables consistently.\u003c\/li\u003e\n  \u003cli\u003eContamination control (including routine mycoplasma monitoring) supports reproducibility in downstream assays.\u003c\/li\u003e\n  \u003cli\u003eUse appropriate negative\/positive controls for the readout (e.g., unstimulated controls, pathway agonists\/antagonists) to contextualize observed changes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- Sources (internal):\n- ATCC Animal Cell Culture Guide — ATCC — https:\/\/www.atcc.org\/resources\/culture-guides\/animal-cell-culture-guide\n- Cell Line Authentication — ATCC — https:\/\/www.atcc.org\/resources\/culture-guides\/cell-line-authentication\n- Biosafety in Microbiological and Biomedical Laboratories (BMBL) — U.S. HHS\/CDC\/NIH — https:\/\/www.cdc.gov\/labs\/BMBL.html\n- Mycoplasma contamination in cell culture — NCBI Bookshelf\/PMC — https:\/\/www.ncbi.nlm.nih.gov\/pmc\/\n- Primary cell culture considerations — Nature Methods — https:\/\/www.nature.com\/nmeth\/\n- Good cell culture practice guidelines — OECD\/ECVAM (concept) — https:\/\/www.oecd.org\/\n--\u003e\n\u003cp style=\"display:none\"\u003eSKU:BHC18500316\u003c\/p\u003e","brand":"iXCells Biotechnologies","offers":[{"title":"Cryopreserved \/ 1 million cells\/vial","offer_id":53197818003821,"sku":"40HU-021-1M","price":1245.92,"currency_code":"USD","in_stock":true},{"title":"Cryopreserved \/ 2 million cells\/vial","offer_id":53197820920173,"sku":"40HU-021-2M","price":1666.08,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/40HU-021-1M-1.png?v=1775378644","url":"https:\/\/www.ebiohippo.com\/products\/human-astrocytes-ipsc-derived-parkinson-s-disease-patient-sporadic-bhc18500316","provider":"BioHippo","version":"1.0","type":"link"}